![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 08, 2020 11:08:05 PM
So, I might as well use them.
I think we’ve seen Psilocybin based money flow in, and a few probably hedged a few more shares because of the low price AND the Covid play.
So let’s REPLAY the non-Covid platforms available to Revive Therapeutics for anyone who maybe new here.
1) Orphan drug status for a CBD drug
2) Non-synthetic “Shroom” stance, and both R&D & supply agreements in place
3) Bucillamine P3 trial seems to be the first step towards a larger market for Pulmonary & Cardiac Inflammation diseases.
4) Oral Thin Strips, in my opinion, this is the biggest potential money maker (patent pending) Revive holds currently. This product will help ensure psilocybin (and other psychedelic drugs) micro dosing, and be an easier and faster transporter for absorption and greater effectiveness. Other companies will want to license this technology from RVVTF.
All told outside of the Covid play, RVVTF has some tools in its belt to rake in between $5-10B over the next 10 years. Which means RVVTF is a $4-8 stock within 2-3 years without the Covid-19 Bucillamine approval.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM